Semin Respir Crit Care Med 2010; 31(2): 147-160
DOI: 10.1055/s-0030-1249115
© Thieme Medical Publishers

Pulmonary Arterial Hypertension and Lung Transplantation

Rajeev Saggar1 , Joseph P. Lynch1 , John A. Belperio1 , S. Samuel Weigt1 , Ariss Derhovanessian1 , Sachin Gupta2 , Rajan Saggar1
  • 1Division of Pulmonary, Critical Care Medicine, and Hospitalists, The David Geffen School of Medicine at UCLA, Los Angeles, California
  • 2Department of Internal Medicine, Irvine Medical Center, University of California, Orange, California
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
30. März 2010 (online)

Preview

ABSTRACT

Heart–lung transplantation (HLT) and lung transplantation (LT) remain important therapies for idiopathic pulmonary arterial hypertension (IPAH), but recent advances in medical therapy can substantially delay or even obviate the need for transplantation, especially in certain PAH populations. By the early 1990s, the advent of epoprostenol, initially introduced as a bridge therapy to transplantation, in fact resulted in a survival advantage for IPAH. These benefits were comparable to those of HLT, and many patients who were thought to be destined for HLT were subsequently removed from active listing. Since 2005, however, the impact of the new lung allocation score (LAS) on IPAH has increased waiting list mortality. In the new millennium, the balance between the role of available medical therapies for PAH, the existing issues of the current LAS regarding the PAH patient, and the inherent morbidity associated with transplantation of PAH, will be critical to optimizing patient outcomes. The following discussion mainly focuses on adult IPAH, with some reference to congenital heart disease (CHD) and secondary PAH.

REFERENCES

Rajeev SaggarM.D. 

Division of Pulmonary, Critical Care Medicine, and Hospitalists, The David Geffen School of Medicine at UCLA

10833 Le Conte Ave., Rm. # 37-131 CHS, Los Angeles, CA 90095-1690

eMail: rasaggar@mednet.ucla.edu